APA

Wentink M. Q., Hackeng T. M., Tabruyn S. P., Puijk W. C., Schwamborn K., Altschuh D., Meloen R. H., Schuurman T., Griffioen A. W. & Timmerman P. (20180326). Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Wentink Madelon Q, Hackeng Tilman M, Tabruyn Sebastien P, Puijk Wouter C, Schwamborn Klaus, Altschuh Daniele, Meloen Rob H, Schuurman Teun, Griffioen Arjan W and Timmerman Peter. 20180326. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Wentink M. Q., Hackeng T. M., Tabruyn S. P., Puijk W. C., Schwamborn K., Altschuh D., Meloen R. H., Schuurman T., Griffioen A. W. and Timmerman P. (20180326). Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Wentink Madelon Q, Hackeng Tilman M, Tabruyn Sebastien P, Puijk Wouter C, Schwamborn Klaus, Altschuh Daniele, Meloen Rob H, Schuurman Teun, Griffioen Arjan W and Timmerman Peter. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. : Proceedings of the National Academy of Sciences of the United States of America. 20180326.